Background-We assessed trends in the performance of transcatheter aortic valve implantation in the United Kingdom from the first case in 2007 to the end of 2012. We analyzed changes in case mix, complications, outcomes to 6 years, and predictors of mortality. Methods and Results-Annual cohorts were examined. Mortality outcomes were analyzed in the 92% of patients from England and Wales for whom independent mortality tracking was available. A total of 3980 transcatheter aortic valve implantation procedures were performed. In successive years, there was an increase in frequency of impaired left ventricular function, but there was no change in Logistic EuroSCORE. Overall 30-day mortality was 6.3%; it was highest in the first cohort (2007)(2008), after which there were no further significant changes. One-year survival was 81.7%, falling to 37.3% at 6 years. Discharge by day 5 rose from 16.7% in 2007 and 2008 to 28% in 2012. The only multivariate preprocedural predictor of 30-day mortality was Logistic EuroSCORE ≥40. During long-term follow-up, multivariate predictors of mortality were preprocedural atrial fibrillation, chronic obstructive pulmonary disease, creatinine >200 μmol/L, diabetes mellitus, and coronary artery disease. The strongest independent procedural predictor of long-term mortality was periprocedural stroke (hazard ratio=3.00; P<0.0001). Nonfemoral access and postprocedural aortic regurgitation were also significant predictors of adverse outcome. Conclusions-We analyzed transcatheter aortic valve implantation in an entire country, with follow-up over 6 years.
T ranscatheter aortic valve implantation (TAVI) has evolved from novel technology to mainstream therapy in only a few years. 1 In 2010, the first randomized trial was published, 2 and in 2011, data from the Placement of Aortic Transcatheter Valve (PARTNER) cohort A were published. 3 Since then, another randomized trial 4 and several registries have reported the uptake of TAVI, both valve specific [5] [6] [7] [8] [9] and country based. [10] [11] [12] [13] [14] [15] Nevertheless, there is still a paucity of data relating to long-term outcomes. Here, we assess the patterns of changing indications, clinical characteristics, procedural details, and outcomes from the UK TAVI registry, which has recorded information for every single patient treated by TAVI, amounting to a total of 3980 procedures by the end of 2012.
Clinical Perspective on p 1190
Methods TAVI was first performed in the United Kingdom in 2007, and by December 2012, 33 centers were active TAVI centers. The early development of UK TAVI up to 2009 has been described. 15 Patient eligibility for a procedure was decided in each center by a multidisciplinary team composed of interventional cardiologists, imaging cardiologists, cardiothoracic surgeons, and anesthetists. The main valve technologies available were the Edwards Sapien and later the Sapien XT, as well as the Medtronic CoreValve. A transfemoral approach was the default strategy for all patients. For those treated with the Medtronic CoreValve, there was later experience with a subclavian and direct aortic approach. For the Edwards Sapien devices, a transapical approach was used when a transfemoral route was not possible, with more recent experience also using a direct aortic approach. From 2011 onward, a small number of valves from St. Jude Medical (Portico), Direct Flow, and JenaValve were implanted. Most centers developed experience with a single manufacturer's devices.
UK TAVI Registry
The UK TAVI data set was collected using the Web-based interface from the National Institute of Cardiovascular Outcomes Research, as previously described. 16 The data set remained unchanged until the end of December 2012. Only patients with a valve implanted in the aortic position were included. Case ascertainment was performed by comparing the center's reported numbers of total procedures with the number of procedures uploaded to the National Institute of Cardiovascular Outcomes Research servers.
Data Cleaning
Range checks to look for extreme values and assessments of internal consistency were applied during upload. All data, including periprocedural complications and complications up to hospital discharge, were self-reported according to the definitions within the national data set. Centers providing records with missing, extreme, or inconsistent values were contacted and asked to check and modify records as appropriate. Missing data were not imputed.
Mortality Tracking
A robust independent system for tracking mortality exists in England and Wales (2 of the 4 countries of the United Kingdom). The vast majority of patients treated were from England or Wales, and for these cases, linkage to data held by the Office of National Statistics was performed by the National Health Service Central Register in March 2014 with the use of each patient's unique National Health Service Number. Validated life status data were available in 3671 of 3980 patients (92%), and this cohort was used for all the survival analyses. All patients provided written informed consent for the TAVI procedure. The National Institute of Cardiovascular Outcomes Research has support under section 251 of the National Health Service (NHS) Act 2006. Under NHS research governance arrangements, formal ethics approval was not required for this study.
Statistical Analysis
Categorical data are presented as percentages, and comparison between groups was performed by the χ 2 test or the Fisher exact test. Numerical data are presented as mean±SD or median (interquartile range), and comparisons were performed with the 2-sample t test or the 2-sample Wilcoxon rank-sum (Mann-Whitney) test. The TAVI program started in mid-2007 with small numbers, so for the purposes of descriptive statistics, cases in 2007 and 2008 were grouped together. To assess whether there was any trend in the occurrence of complications by the year of operation, a χ 2 test for trend was performed, and univariate logistic regression was used to assess the risk of complications from the use of the Medtronic or Edwards Sapien valve. Time-to-event data analysis was performed with the Cox proportional hazards model. Kaplan-Meier survival curves were drawn to assess differences between groups for the time to an event. For the Cox model, univariate analysis of each of the possible predictors of the outcome was tested, and only those variables that were significant at P<0.05 were included in a multivariable model. A stepwise option was used to determine independent predictors of the outcome variables. Statistical analysis was performed with Stata version 12.1 statistical software (StataCorp, College Station, TX). (Table 1) . There were no differences in age, sex, renal dysfunction, diabetes mellitus, previous myocardial infarction, previous cardiac surgery, previous percutaneous coronary intervention (either before TAVI or as a hybrid), pulmonary disease, and atrial fibrillation in each successive year. However, there was an increase in the treatment of patients with impaired left ventricular function; the percentage with left ventricular ejection fraction <30% increased from 5.9% in 2007 and 2008 to 10 .2% in 2012. However, this increase was not associated with a change in the calculated Logistic EuroSCORE (mean, 21.9%; median, 18.4%), either overall or when examined by decile ranges of Logistic EuroSCORE. The cumulative frequency distribution curves for each cohort are indistinguishable (Figure 1 ). In addition, fewer patients with previous stroke and peripheral vascular disease underwent TAVI in 2012 compared with 2007 and 2008. in 19.6%). The use of nonfemoral access evolved over time. There were an increase in the use of a direct aortic approach for both Edwards and CoreValve implantation and a slight reduction in the use of the transapical (Edwards) and subclavian (CoreValve) approaches.
Results

Patients
Although general anesthesia was used in 86.7% of cases, there was an increase in non-general anesthesia methods from 13% in 2007 and 2008 to 16% by 2012 (P=0.011).
Postprocedural median length of stay was 8 days (interquartile range, 6-13 days), with a significant decrease from 10 to 8 days in successive cohorts. The percentage of patients discharged on the third postprocedural day was stable at 5.6%, but the number of patients who could be discharged by the fifth postoperative day increased from 16.7% in 2007 and 2008 to 28 .5% in 2012.
Outcomes
Mortality
Mortality tracking was performed on March 1, 2014, for the English and Welsh patients (3671 of 3980). Time from implantation to census ranged from 27 months to 7.01 years.
Mortality at 30 Days
Unadjusted 30-day all-cause mortality for the whole cohort was 6.3%. 
Mortality at 1 Year
Survival at 1 year was 81.7%; at 2 years, 72.8%; at 5 years, 46.9%; and at 6 years, 37.3% (Table I in the online-only Data Supplement). After early attrition, the Kaplan-Meier curve showed a linear decrease in survival with time ( Figure 2 ). stable. For example, survival at 3 years was between 62% and 66% (Table II in the online-only Data Supplement). There is, however, a higher survival at longer follow-up in more recent cohorts. For example, at 4 years, survival for the 2009 cohort was 55% and for the 2011 cohort had risen to 65%. In addition, survival at 1, 2, and 3 years was higher in the 2012 cohort than all previous years. These trends can be seen when the KaplanMeier curves from 3 cohorts are overlaid ( Figure 3 ).
Long-Term Survival
Procedural Complications
The frequency of stroke decreased from 3. Emergency conversion to surgery in the catheterization laboratory was required in 21 patients (0.53%), of whom 14 (67%) died in hospital. Bailout percutaneous coronary intervention occurred in 12 patients, of whom 6 (50%) died before discharge.
Aortic Regurgitation
There was no temporal trend in post-TAVI aortic regurgitation (AR), assessed as any AR versus no AR (P=0.072 for trend), as severe AR versus no severe AR (P=0.31 for trend), or by category of AR.
Complication by Valve Type
There was no significant difference in the incidence of inhospital stroke or major vascular injury (Table IV in the online-only Data Supplement). CoreValve was associated with a higher incidence of post-TAVI AR than Edwards (odds ratio for any AR, 1.94; P<0.0001). This was particularly apparent in the moderate-AR category (15.6% versus 6.8%).
Pacemaker implantation was also observed more frequently after CoreValve than Edwards (odds ratio, 3.20; P<0.0001) implantation but reduced markedly with CoreValve implantation from ≈29% to ≈15% in more recent years (P<0.0001).
Predictors of Mortality
Univariate and multivariate predictors of mortality were assessed at the 30-day, 1-year, and 2-years follow-up. Results are presented in Tables V through VII in the online-only Data Supplement.
Preprocedural Associations With Mortality
Mortality at 30 Days Univariate predictors of 30-day mortality were moderately impaired left ventricular function (left ventricular ejection fraction, 30%-49%), peripheral vascular disease, chronic obstructive pulmonary disease, creatinine >200 μmol/L, and logistic EuroSCORE, but only when the score was ≥40. Prior cardiac surgery was associated with a trend to lower mortality, but the presence of coronary disease was not related to outcomes. However, in a multivariate analysis, Logistic EuroSCORE ≥40 was the only independent predictor of 30-day mortality.
Mortality at 1 and 2 Years
Predictors of 1-and 2-year survival show a different pattern. The independent predictors of 1-year mortality were preprocedural atrial fibrillation, diabetes mellitus, chronic obstructive pulmonary disease, creatinine >200 μmol/L, and Logistic EuroSCORE. The Kaplan-Meier survival curve for atrial fibrillation shows a progressive separation to ≈3 years ( Figure 5 ). At 2 years, the same predictors persist except for diabetes mellitus, which is no longer an independent predictor. In addition to the other 1-year predictors, the presence of coronary disease becomes independently associated with mortality at 2 years, and previous cardiac surgery is associated with improved outcomes. Although Logistic EuroSCORE was a predictor of 30-day mortality only at extreme values, by the 1-and 2-year follow-up, a much more graded association with each decile is observed in the survival curves ( Figure 6 ).
Procedural Associations of Mortality
There was no difference in survival between the 2 main valve types on multivariate analysis at any time point. As expected, the presence of postprocedural AR (moderate or severe) was associated with lower long-term survival on multivariate analysis at 1 and 2 years, with the survival curves separating early but then running parallel from 2 to 7 years (Figure 7) . At 30 days, transfemoral access was associated with lower mortality compared with nontransfemoral approaches. This association was also present at the 1-and 2-year follow-up.
Although stroke was an uncommon outcome, it was associated with a markedly lower short-and long-term survival (at 30 days: hazard ratio, 4.81 [P<0.0001]; at 2 years: hazard ratio, 3.00 [P<0.0001]). The survival curve shows a large early attrition (Figure 8 ). Vascular complications were associated with increased mortality at follow-up (at 2 years: hazard ratio, 1.52; P=0.043). However there was no association between the need for pacing and subsequent mortality in the short or long term.
Learning Curve
We tried to address the issue of a potential learning curve (Table 3) . Thirty-day mortality for the first 50 cases performed in every center was 6.5% compared with a 30-day mortality of all subsequent cases of 6.2% (P=0.7). Because of the wide variation in the total case volume of UK centers, we also assessed the 10 highest-volume centers (all of which have performed >100 cases) and compared the 30-day mortality of their first 50 procedures with all their subsequent ones and their first 100 procedures with all subsequent ones. Again, although there was a trend for higher mortality in the early cases, it was not statistically significant. We looked for possible differences between early adopters of TAVI and later starters, and again, only a trend was identified. We also assessed a possible learning curve for the most recent 5 centers to start a TAVI program (starting between 2009 and 2010). We found a statistically significant higher mortality in their first 50 cases compared with their subsequent cases. Finally, we explored the association between total procedure volume in every center (which varied from <30 to >300) and the 30-day mortality for every center using linear regression and found no statistically significant relationship (P=0.9).
Discussion
We present the trends in treatment and predictors of outcome in an all-comer registry that has captured an entire country's experience with TAVI from the first implantation in 2007, with follow-up of >6 years and a sizable number of patients alive and at risk at 6 years. Our study represents the largest longterm follow-up analysis of its kind to date. The short-and medium-term outcomes in our registry are broadly comparable with those in other reported registries, the follow-up for which (except for the Canadian study 5 ) is limited to <3 years. 6, 8, 10, 12, 13, 17 In the present analysis of the UK TAVI registry, we show that there has been very little change in the characteristics of patients treated in the United Kingdom by TAVI from 2007 to 2012, with the only demographic shift being toward the treatment of patients with lower left ventricular ejection fraction. This contrasts with the French experience in which there was a decrease in Logistic EuroSCORE for patients treated in 2012 compared with 2011 12 and may relate to differences in commissioning structures. In 2009, a UK TAVI Steering Group was formed. This was a collaboration of the 2 main professional societies (British Cardiovascular Intervention Society and the Society of Cardiothoracic Surgeons), the Department of Health, and commissioners and regulators of UK health care (including the National Institute of Clinical Excellence). This group released a position statement that mandated a multidisciplinary team approach for the selection of patients, the requirement that TAVI be performed only in surgical centers, and the implication that funding would be restricted to the treatment of highrisk patients whose Logistic EuroSCORE was expected to be >20 and Society of Thoracic Surgeons score was >10. It seems likely that compliance with this guidance was responsible for the lack "EuroSCORE creep" in the United Kingdom during this time period. 18 We report relatively high 30-day and long-term mortality in the initial 2007 and 2008 cohort. Thereafter. early and late outcomes have remained similar until the most recent (2012) cohort, when 1-and 2-year survival (but not 30-day survival) rates were better than for any earlier cohort. This is likely to reflect changes in patient selection. Although there was no change in measured demographic features, case selection includes clinical features not captured in current data sets. The multidisciplinary teams selecting patients for TAVI have gained increasing experience over time and may be better at selecting patients who are most likely to benefit from TAVI. However, it would be a concern if we observe a move away from those patients who, although extremely frail, may have the most to gain, as did cohort B of the PARTNER trial. 19 There has been an increase in earlier discharge of these elderly patients so that more than a quarter of the 2012 cohort were discharged by the fifth day after TAVI.
We identified no isolated preprocedural multivariate predictors of 30-day outcomes, supporting the observation that TAVI is remarkably well tolerated in the elderly and consistent with the lack of an accepted scoring system to predict early outcomes. Studies of EuroSCORE II show an area under the receiver-operating characteristic curve of only 0.7 20 and 0.59 from the French registry. 21 In our study, Logistic EuroSCORE was a predictor of 30-day outcome only when it was extremely high (≥40). This relationship with procedural outcome is reflected in the survival curves, which for Logistic EuroSCORE >40 separate sharply during early follow-up. Nevertheless, each decile of Logistic EuroSCORE becomes a very strong predictor of later outcomes, reflecting the intrinsic comorbidities of patients. This is illustrated by the survival curves, which begin to fan out at longer follow-up. It is consistent with the finding that multivariate predictors of later outcome relate mainly to comorbidity and was observed in other registries at later follow-up. 8, 12, 13 In addition, the presence of preprocedural atrial fibrillation is strongly associated with later mortality. Similarly, in the Canadian registry, chronic atrial fibrillation was significantly associated with adverse outcomes only at 1 year, not 30 days, 17 and in the German registry, a strong association with longer-term outcome was also observed. 13 No association was documented in the Italian registry for a median follow-up of 69 days. 8 These data were not reported in the French 12 or US PARTNER trials. 2, 3 In line with previous observations, those patients who can be treated by the femoral route have a lower mortality than those for whom an alternative route is needed. 3, 12, 22 Although the increased comorbidity of the latter patients is undoubtedly a factor in their poorer survival, the contribution of the nonfemoral procedure itself has been debated. 23 Whether the direct aortic approach 24 offers a lower operative risk than a transapical approach is not yet established. Theoretical benefits include less risk of apical rupture and delayed pseudoaneurysm formation, less interference with postoperative respiratory dynamics, and no risk to left ventricular function caused by an apical purse-string suture. The use of the direct aortic approach has been increasing, although this registry shows that the unadjusted survival rates for the direct aortic approach and the transapical approach are almost identical at 1 to 2 years.
Surgical femoral approaches were used in ≈11% of procedures in 2007 to 2009 but in later years increased to ≈20%. This was observed despite a reduction in the size of many TAVI delivery systems. This might be explained by early attempts to make TAVI as "noninvasive" as possible with the use of percutaneous transfemoral access even in settings where anatomy was unfavorable. Experience has shown that this can result in peripheral vascular complications that might be avoided with the use of a surgical femoral approach. Our data support this explanation, showing higher such complications during the early years when surgical femoral access rates were low. As the sizes of access sheaths reduce further, we might anticipate a future reduction in surgical femoral procedures.
In common with other registries, we found no difference in outcomes according to the need for pacing or the presence of preprocedural left bundle-branch block. There is a consistently low rate of periprocedural stroke, but when this complication occurred, it had the strongest independent association with a high early and late mortality.
The better outcomes we observed in patients with prior cardiac surgery were seen in PARTNER, 25 were observed as a trend in the Canadian registry, 17 but were not seen in either the Italian or German registry. 8, 13 The association in our registry might be explained by a reluctance to perform redo surgery, favoring TAVI in patients with relatively little other comorbidity. The fact that this remains a predictor of a good outcome on multivariate analysis at 2 years supports the concept that the data set may be missing important measures of comorbidity.
The association between postprocedural AR and outcomes has been widely reported and is reflected in our analysis. Whether AR causes this adverse outcome or is a confounding marker cannot be determined from observational studies. We have previously shown a differential association of adverse outcome when comparing the Edwards and CoreValve devices in the UK TAVI registry. Moderate to severe AR, although seen more frequently after CoreValve procedures, was associated with adverse outcome only after implantation of an Edwards valve. 26 The development of devices with dedicated sealing skirts may mean that this issue will be of less clinical importance in the future. In common with other studies, we found no statistically significant difference in mortality outcomes between the Edwards and CoreValve devices. 27, 28 Learning curves can be individual, institutional, and global as more is learned by everyone from everyone else. We tried to explore the issue by looking at early versus later cases and centers that started a TAVI program early (early adopters) compared with later adopters. Against the background of an overall gradual reduction in 30-day mortality with time, we have found only a trend to higher 30-day mortality in cases treated early in a center's experience compared with subsequent cases. This observation is in keeping with a rigorous proctoring program that has formalized the learning process in the United Kingdom. The only exception was a statistically higher mortality in the first 50 cases of the 5 centers that started their TAVI programs most recently. Although this might argue against a global learning curve (one would hope late adopters would learn from the early worldwide experience and have less of a learning curve), the explanation might simply be that the most recent cases performed by these centers have a particularly low mortality (only 3.4%). Finally, we found no relationship between the total case volume of a center and 30-day mortality.
Improved understanding of key intrinsic patient factors associated with poorer long-term outcomes may help in guiding appropriate patient selection for this very well-tolerated procedure.
Limitations
Data completeness in this national registry was good. Nevertheless, the data are self-reported. Although there are internal consistency and range checks and units are contacted to clarify missing and unexpected values, the data are not subject to independent external validation. Mortality tracking is extremely reliable and independently adjudicated but was available only for England and Wales (which represented the sites of 92% of procedures during this study period). This study is a description of trends and associations, and no conclusions on possible cause and effect can be drawn.
Conclusions
We present the early evolution of TAVI in the United Kingdom using a national registry that includes every patient treated by TAVI and followed up for >6 years. Over this period of time, the overall Logistic EuroSCORE has remained unchanged, although more patients with lower left ventricular ejection fraction were treated. After an initial improvement in survival after 2007 and 2008, short-and long-term outcomes have remained stable, improving further in the most recent (2012) cohort. In addition, a higher percentage of patients were discharged early after the procedure. Short-term (30 day) outcome is difficult to predict on the basis of preprocedural factors, but in the medium and longer term, poor outcome is associated with intrinsic patient characteristics. 
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